Comparative effects of non-pharmacological interventions on anxiety, depression and quality of life in individuals with substance use disorders: A systematic review and network meta-analysis.

J Affect DisordMay 2, 2026 (epub)
Clinical ResearchPsychiatry

Haoran Luo, Yiman Xiong, Xianming Ding et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the efficacy of non-pharmacological interventions for anxiety, depression, and quality of life in individuals with substance use disorders (SUDs). Analyzing 117 RCTs with 11,177 participants, the study found that neuromodulation was the top-ranked intervention for anxiety and quality of life, while mind-body therapy ranked highest for depression. Short-term improvements in anxiety and depression were noted, but quality of life effects were uncertain.

Key findings

  • Neuromodulation showed significant reductions in anxiety symptoms compared to control.
  • Mind-body therapy ranked highest for reducing depression symptoms among interventions.
  • Quality of life improvements were uncertain, with imprecise estimates at the earliest post-intervention time point.
  • Subgroup analyses indicated varying effects based on country development level and intervention duration.

Why it matters

Understanding the comparative effectiveness of non-pharmacological interventions can guide clinicians in selecting appropriate treatments for individuals with substance use disorders, potentially improving mental health outcomes and quality of life.

Source

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.